Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Sirnaomics Inc. has 6 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 5 distinct art units. The prosecution involves 6 distinct examiners. The busiest examiner identified in the data is HUDSON, AMY ROSE, who accounts for 1 pending office action. With the pending actions spread across 5 art units, the portfolio demonstrates a broad technical distribution within its sector.
The management of 6 pending office actions requires coordination across multiple examiners. Since the actions are spread across 5 art units, the legal team must navigate various internal policies and examination styles within the USPTO. The presence of HUDSON, AMY ROSE as the busiest examiner with 1 pending office action indicates that the workload is not concentrated under any single individual. This distribution suggests that the company is pursuing diverse technological paths within the Biotechnology & Pharmaceuticals space. Practitioners should be prepared for a variety of examiner perspectives given the high number of distinct examiners involved in the current prosecution cycle. The lack of concentration in a single art unit necessitates a versatile approach to patent prosecution.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 4 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUDSON, AMY ROSE | 1 | 74.9% | +11.5% |
| POLIAKOVA-GEORGAN, EKATERINA | 1 | 64.0% | +18.0% |
| GIBBS, TERRA C | 1 | 63.7% | +10.3% |
| ARIETI, RUTH SOPHIA | 1 | 46.7% | +71.1% |
| GREENE, IVAN A | 1 | 18.7% | +6.4% |
| COHEN, MICHAEL P | 1 | 58.7% | +27.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18179410 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | GIBBS, TERRA C | 6d |
| 18126145 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | POLIAKOVA-GEORGAN, EKATERINA | 9d |
| 17935022 | NANOPARTICLE PHARMACEUTICAL COMPOSITIONS WITH REDUCED NANOPARTICLE SIZE AND IMPROVED POLYDISPERSITY INDEX | GREENE, IVAN A | 22d |
| 18355280 | METHODS FOR INDUCING ADIPOSE TISSUE REMODELING USING RNAI THERAPEUTICS | HUDSON, AMY ROSE | — |
| 17935014 | NANOPARTICLE FORMULATIONS FORMED FROM HISTIDINE-LYSINE COPOLYMERS | COHEN, MICHAEL P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18179410 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | GIBBS, TERRA C | 6d |
| 18126145 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | POLIAKOVA-GEORGAN, EKATERINA | 9d |
| 18355280 | METHODS FOR INDUCING ADIPOSE TISSUE REMODELING USING RNAI THERAPEUTICS | HUDSON, AMY ROSE | — |
| 18170971 | PRODUCTS AND COMPOSITIONS | ARIETI, RUTH SOPHIA | — |
| 17935014 | NANOPARTICLE FORMULATIONS FORMED FROM HISTIDINE-LYSINE COPOLYMERS | COHEN, MICHAEL P | — |
| Art Unit | Apps |
|---|---|
| 1635 | 2 |
| 1636 | 1 |
| 1637 | 1 |
| 1619 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18355280 | METHODS FOR INDUCING ADIPOSE TISSUE REMODELING USING RNAI THERAPEUTICS | HUDSON, AMY ROSE | 1636 | §103§112 | Final Rejection | — | Pending | Jul 19, 2023 |
| 18126145 | NUCLEOSIDE CONTAINING siRNAS FOR TREATING VIRAL DISEASES | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §102§103Other | Non-Final OA | 9d | Pending | Mar 24, 2023 |
| 18179410 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | GIBBS, TERRA C | 1635 | §103§112Other | Final Rejection | 6d | Pending | Mar 07, 2023 |
| 18170971 | PRODUCTS AND COMPOSITIONS | ARIETI, RUTH SOPHIA | 1635 | §103§112DP | Non-Final OA | — | Pending | Feb 17, 2023 |
| 17935022 | NANOPARTICLE PHARMACEUTICAL COMPOSITIONS WITH REDUCED NANOPARTICLE SIZE AND IMPROVED POLYDISPERSITY INDEX | GREENE, IVAN A | 1619 | §103Other | Final Rejection | 22d | Pending | Sep 23, 2022 |
| 17935014 | NANOPARTICLE FORMULATIONS FORMED FROM HISTIDINE-LYSINE COPOLYMERS | COHEN, MICHAEL P | 1612 | §103§112 | Final Rejection | — | Pending | Sep 23, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial